Kamada (KMDA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kamada (KMDA) has a cash flow conversion efficiency ratio of 0.039x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA10.42 Million ≈ $27.92K USD) by net assets (ILA265.23 Million ≈ $711.08K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Kamada to measure how many days the company can operate on defensive assets alone.
Kamada - Cash Flow Conversion Efficiency Trend (2007–2024)
This chart illustrates how Kamada's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Kamada Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kamada ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bijou Brigitte modische Accessoires Aktiengesellschaft
XETRA:BIJ
|
0.127x |
|
Suzhou Mingzhi Technology Co. Ltd. A
SHG:688355
|
0.130x |
|
EUROSEAS LTD DL -01
F:2LE1
|
N/A |
|
GemVax&KAEL Co.Ltd
KQ:082270
|
0.181x |
|
Mobiltel Iletisim Hizmetleri Sanayi ve Ticaret AS
IS:MOBTL
|
-0.014x |
|
AMTD Digital Inc.
NYSE:HKD
|
0.018x |
|
BTS Group AB (publ)
ST:BTS-B
|
-0.001x |
|
Yem Chio Co Ltd
TW:4306
|
-0.007x |
Annual Cash Flow Conversion Efficiency for Kamada (2007–2024)
The table below shows the annual cash flow conversion efficiency of Kamada from 2007 to 2024. For the full company profile with market capitalisation and key ratios, see KMDA market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ILA259.46 Million ≈ $695.61K |
ILA47.59 Million ≈ $127.60K |
0.183x | +937.34% |
| 2023-12-31 | ILA244.02 Million ≈ $654.21K |
ILA4.32 Million ≈ $11.57K |
0.018x | -89.11% |
| 2022-12-31 | ILA176.02 Million ≈ $471.90K |
ILA28.59 Million ≈ $76.64K |
0.162x | +425.62% |
| 2021-12-31 | ILA176.82 Million ≈ $474.06K |
ILA-8.82 Million ≈ $-23.64K |
-0.050x | -146.63% |
| 2020-12-31 | ILA178.64 Million ≈ $478.92K |
ILA19.11 Million ≈ $51.22K |
0.107x | -47.51% |
| 2019-12-31 | ILA135.32 Million ≈ $362.79K |
ILA27.57 Million ≈ $73.92K |
0.204x | +117.11% |
| 2018-12-31 | ILA112.38 Million ≈ $301.28K |
ILA10.55 Million ≈ $28.27K |
0.094x | +115.90% |
| 2017-12-31 | ILA89.49 Million ≈ $239.92K |
ILA3.89 Million ≈ $10.43K |
0.043x | +52.93% |
| 2016-12-31 | ILA66.74 Million ≈ $178.94K |
ILA1.90 Million ≈ $5.09K |
0.028x | +114.74% |
| 2015-12-31 | ILA72.51 Million ≈ $194.39K |
ILA-13.98 Million ≈ $-37.48K |
-0.193x | -57.44% |
| 2014-12-31 | ILA80.99 Million ≈ $217.14K |
ILA-9.92 Million ≈ $-26.59K |
-0.122x | -185.86% |
| 2013-12-31 | ILA89.97 Million ≈ $241.21K |
ILA-3.85 Million ≈ $-10.33K |
-0.043x | +85.28% |
| 2012-12-31 | ILA28.39 Million ≈ $76.12K |
ILA-8.26 Million ≈ $-22.15K |
-0.291x | -801.65% |
| 2011-12-31 | ILA22.67 Million ≈ $60.79K |
ILA940.36K ≈ $2.52K |
0.041x | -89.67% |
| 2010-12-31 | ILA26.49 Million ≈ $71.01K |
ILA10.63 Million ≈ $28.50K |
0.401x | +192.43% |
| 2009-12-31 | ILA30.15 Million ≈ $80.83K |
ILA-13.09 Million ≈ $-35.10K |
-0.434x | +56.84% |
| 2008-12-31 | ILA12.64 Million ≈ $33.89K |
ILA-12.72 Million ≈ $-34.11K |
-1.006x | -456.76% |
| 2007-12-31 | ILA69.57 Million ≈ $186.51K |
ILA-12.57 Million ≈ $-33.71K |
-0.181x | -- |
About Kamada
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmuniza… Read more